The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Learn more about whether Bausch + Lomb Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

This prospective case-control study included 85 patients with lung involvement related to the COVID-19 virus and a group of ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today ...

Excessive screen time and chronic stress, especially in young people, disrupt circadian rhythms and immune function, ...

It was there that Mr Pearce, 40, was diagnosed with a branch retinal vein occlusion, where one of the veins in the retina ...